Table. 2—

Time to disease progression or death in the Bosentan Use in Interstitial Lung Disease-1 study

Treatment months	Patients at risk n
	Placebo	Bosentan
Whole study population
0	83	71
3	79	67
6	72	59
9	61	55
12	40	32
Subpopulation^#
0	50	49
3	47	47
6	42	42
9	36	41
12	24	22

^#: patients with biopsy-proven idiopathic pulmonary fibrosis.